Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19

Inclusion Criteria: 1. Informed consent from patient or legal representative. 2. Male or female, aged ≥ 18 years; 3. Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source; 4. Signs of respiratory failure requiring oxygen therapy 5. Hospitalized for up to 36h with non-invasive ventilation 6. Negative result for pregnancy test (if applicable). Exclusion Criteria: 1. Participating in another RCT in the past 12 months; 2. Known allergy to nitazoxanide 3. Severely reduced LV function; 4. Severely reduced renal function; 5. Pregnancy or breast feeding; 6. Use of hydroxychloroquine and/or azithromycin in the past 15 days; 7. Any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products